Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
All patients treated with ocrelizumab (Ocrevus; Genentech) were B-cell depleted and had lower SARS-CoV-2 antibody response than any other patients in the study. Those who were depleted of B-cells had lower severe acute respiratory syndrome coronavirus 2 antibody response.
In this NeurologyLive Peer Exchange, Richard S. Bedlack, MD, PhD, MS; Ammar Al-Chalabi, MB, ChB, PhD; Jinsy A. Andrews, MD, MSc; and Jeremy M. Schefner, MD, PhD, discuss the current treatment landscape for amyotrophic lateral sclerosis and provide insights into ongoing clinical trials and recent results.
The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients and why its home-use feasibility may be a huge advantage for them, and the reasons behind the sudden movement toward these post-stroke rehab systems.
William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed the aim of his practice’s study, as well as his hopes that it could help provide a rationale to adjust Medicare legislation that makes providing CPAP to patients difficult.
In this NeurologyLive Peers & Perspectives, Jill Dehlin, RN, and Amaal J. Starling, MD, discuss how to provide patients with migraine access to support programs and take a proactive role in managing their condition, as well as discuss the challenges and stigmas associated with migraine.
Don't miss your chance to register for next week's free webinar, part of our series the Ever-Changing Face of Multiple Sclerosis, put on in partnership with the Consortium of Multiple Sclerosis Centers. You'll join Ahmed Obeidat, MD, PhD; Mitch Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis. To register for this program, click here.
To view the enduring version of the first program, click here for our Future Leaders in Neurology section.